Drug intelligence / Profile preview

ciprofloxacin + levofloxacin

Development stage
Preclinical
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

The combination of ciprofloxacin and levofloxacin is a dual fluoroquinolone antibiotic therapy that has been studied for its synergistic effects against various bacterial infections. Both drugs work by inhibiting bacterial DNA synthesis through targeting DNA gyrase and topoisomerase IV, but they have some differences in their spectrum of activity and pharmacokinetic properties. ## Mechanism of Action Both ciprofloxacin and levofloxacin inhibit bacterial DNA gyrase and topoisomerase IV, which are essential enzymes for bacterial DNA replication and repair[1][2]. These enzymes are type II topoisomerases with unique functions in bacterial cells. DNA gyrase introduces negative supercoils into DNA during replication to relieve torsional strain, while topoisomerase IV is crucial for "unlinking" newly replicated chromosomes during cell division[7]. When used in combination, these fluoroquinolones show enhanced antimicrobial activity against various pathogens, particularly Pseudomonas aeruginosa and Acinetobacter species[1][2]. Studies have demonstrated synergistic effects when these antibiotics are combined with other antimicrobials such as beta-lactams or aminoglycosides[1]. ## Clinical Applications The combination has been studied for treating: - Urinary tract infections (UTIs)[9] - Respiratory tract infections[3] - Infections caused by Pseudomonas aeruginosa and Acinetobacter species[1][2] - Genitourinary infections[4] Research suggests that both ciprofloxacin and levofloxacin may have potential in supportive therapy for bladder conditions[4]. When used for UTIs, studies indicate that while there's no significant difference in efficacy between the two drugs, levofloxacin has the advantage of once-daily dosing compared to ciprofloxacin's twice-daily regimen[9]. ## Pharmacokinetics Levofloxacin has nearly complete oral bioavailability (approximately 99%) and reaches maximum plasma concentration in 1-2 hours after administration[7]. Ciprofloxacin's absorption can be affected by calcium-containing products like dairy, which should be separated from dosing times[3]. ## Side Effects and Safety Both antibiotics share similar side effect profiles, including: - Tendon ruptures - Nerve damage - Mental health effects - Blood sugar changes - Aortic wall tears - Cardiac arrhythmias - Severe skin reactions[3] They also have numerous drug interactions with medications such as: - Warfarin - Theophylline - Diabetes medications - Tricyclic antidepressants - Metal-containing supplements (magnesium, aluminum, zinc, iron) - Sucralfate[3][5] Due to these serious risks, these fluoroquinolones are typically avoided for mild infections when alternative antibiotics are available[3]. ## Research Findings In laboratory studies using checkerboard assays and time-kill curves, the combination of these fluoroquinolones with beta-lactams or aminoglycosides showed enhanced activity against various bacterial strains[1][2]. Specifically, levofloxacin and ciprofloxacin combined with ceftazidime, as well as levofloxacin plus amikacin, demonstrated synergistic effects against all tested strains[1][2].

02

Targets

DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on ciprofloxacin + levofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofloxacin + levofloxacin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call